You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

Not yet recruiting
  • T-cell Lymphoma Patients After First-line Treatment Failure
  • SHR2554; Chidamide analog tablets
  • SHR2554 analog tablets; Chidamide
  • (no location specified)
Nov 5, 2023

T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)

Recruiting
  • T-Cell Acute Lymphocytic Leukemia
  • CD7 CAR-T
  • Langfang, Hebei, China
    Hebei Yanda Hospital
Jun 26, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)

Not yet recruiting
  • Peripheral T-cell Lymphoma
  • Linperlisib in combination with CHOP
  • (no location specified)
Jul 10, 2023

Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

Not yet recruiting
  • Relapsed or Refractory T-cell Lymphomas
  • Sendai-shi, Miyagi, Japan
    Local Institution - 0001
Sep 12, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)

Recruiting
  • Lymphoblastic Lymphoma
  • +2 more
  • BEAM-201
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jun 2, 2023

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

    Recruiting
    • Newly Diagnosed Peripheral T-cell Lymphoma
    • Duvelisib, Chidamide
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Jul 27, 2023

    Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

    Not yet recruiting
    • Cutaneous T Cell Lymphoma
    • Fungoides Mycosis Sezary Syndrome
    • Ann Arbor, Michigan
      University of Michigan Comprehensive Cancer Center
    Jul 13, 2023

    CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

    Not yet recruiting
    • Lymphoma
    • Chimeric Antigen Receptor
    • (no location specified)
    Oct 24, 2023

    nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

    Recruiting
    • nk/T-cell Lymphoma
    • +2 more
    • XPO1 inhibitor
    • Beijing, Haidian, China
      ChinaPLAGH
    Apr 18, 2023